Clinical trial
A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)
NCT06592664 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)
- Lead sponsor
- Lisata Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- January 31, 2030
- Completion date
- January 31, 2040
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic pancreatic cancer, pancreas adenocarcinoma, pancreas cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pdac, pdac - pancreatic ductal adenocarcinoma, unresectable pancreatic cancer